Simon Schwartz Navarro

Senior scientist and advisor with specific interest in Nanomedicine and Advanced Therapies applied to unmet clinical needs. I am also acting as strategy coordinator to facilitate programs and initiatives that foster innovation in new treatments and diagnostic tools.

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)

Vall Hebron Institut de Recerca

Cap de Secció
Bioquímica

Cross-departmental services

Simon Schwartz Navarro

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)

Vall Hebron Institut de Recerca

Cap de Secció
Bioquímica

Cross-departmental services

Currently acting as Strategy director of biobanking and bioresources at Vall d'hebron Campus. President of the European Society of Nanomedicine and Executive Board member of the International Society of Nanomedicine. Former director general of the Blood and Tissue Banc of Catalonia. Former director of CIBBIM-Nanomedicine. Former scientific associate director of CIBER-BBN and coordinator of technology transfer. Former director assistance of translational research at VHIR. H-index of 40, with more that 115 high impact publications and 17 transferred patents. Co-founder of 3 biotech companies (i.e, Bsure Medical ltd). Science Advisor of the European Nanomedicine Characterization Laboratory (EU-NCL). Member of the editorial Board of Precision Nanomedicine, J. Nanotechnology and of J. of Nanotheranostics. Former editorial Board member of Eur. J. Nanomedicine and Nanomedicine-NBM.

Projects

A Nanotechnologic Platform for the Targeted Drug and Gene Delivery Against the Advanced Cancer

IP: Simon Schwartz Navarro
Collaborators: -
Funding agency: CERCA (Centres de Recerca de Catalunya)
Funding: 9070
Reference: 2018/GINJOL/SCHWARTZ
Duration: 26/02/2018 - 18/06/2019

Desenvolupament de noves nanopartícules funcionals dirigides al nòdul limfàtic per a l'eliminació del reservori latent de VIH

IP: María José Buzón Gómez
Collaborators: Desenvolupament de noves nanopartícules funcionals dirigides al nòdul limfàtic per a l'eliminació del reservori latent de VIH, Félix Pumarola Segura, Juan Lorente Guerrero, Laura García Latorre, Jordi Temprana Salvador, Joaquin Seras Franzoso, Marc Pellicer Sarasa, David Perea Pérez, Simon Schwartz Navarro, Jordi Navarro Mercadé, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Judit Grau Exposito, Meritxell Genesca Ferrer, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael
Funding agency: Fundació La Marató de TV3
Funding: 199998.75
Reference: 20180510
Duration: 10/05/2019 - 31/12/2022

Evolvable platform for designing cancer treatment strategies using nanoparticles (EVO-NANO)

IP: Evolvable platform for designing cancer treatment strategies using nanoparticles (EVO-NANO)
Collaborators: Joaquin Seras Franzoso, Simon Schwartz Navarro, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Belen Garcia Prats
Funding agency: EUROPEAN COMMISSION
Funding: 568847.5
Reference: EVO-NANO_H2020FETOPEN2017
Duration: 01/10/2018 - 31/03/2022

SAFETY TESTING IN THE LIFE CYCLE OF NANOTECHNOLOGY-ENABLED MEDICAL TECHNOLOGIES FOR HEALTH..

IP: SAFETY TESTING IN THE LIFE CYCLE OF NANOTECHNOLOGY-ENABLED MEDICAL TECHNOLOGIES FOR HEALTH..
Collaborators: Marc Miquel Moltó Abad, Olga Sánchez- Maroto Carrizo, Julia German Cortes, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, SAFETY TESTING IN THE LIFE CYCLE OF NANOTECHNOLOGY-ENABLED MEDICAL TECHNOLOGIES FOR HEALTH.., Belen Garcia Prats, Angels Alcina Mila, Alejandro López Targa, Maria Fidel Lledò, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Simon Schwartz Navarro
Funding agency: EUROPEAN COMMISSION
Funding: 649580
Reference: SAFE-N-MEDTECHEC_H2020-NMBP2018
Duration: 01/04/2019 - 30/09/2023